Soleno Therapeutics Surges to Top 59 with $103.8 Million Trading Volume

On March 27, 2025, Soleno Therapeutics (SLNO) saw a significant surge in trading volume, reaching $103.8 million, marking a 555.05% increase from the previous day. This surge placed Soleno among the top 59 most actively traded stocks for the day, with the stock price rising by 37.61%.

Soleno Therapeutics has announced that it will be presenting at the upcoming 2025 Annual Meeting of Shareholders. The meeting will be held on April 15, 2025, and will provide an opportunity for shareholders to discuss the company's performance and future plans. The company has also announced that it will be hosting a webcast of the meeting, allowing shareholders who are unable to attend in person to participate remotely.

Soleno Therapeutics has also announced that it has received approval from the FDA to begin a Phase 3 clinical trial for its lead drug candidate, DCCR. The trial will evaluate the safety and efficacy of DCCR in patients with type 2 diabetes. The company has stated that it expects to enroll up to 1,000 patients in the trial, with results expected in the second half of 2026.

Soleno Therapeutics has also announced that it has entered into a strategic partnership with a leading biotechnology company to develop and commercialize its pipeline of drug candidates. The partnership will focus on the development of new treatments for rare diseases, with a particular emphasis on metabolic disorders. The company has stated that it expects the partnership to accelerate the development of its pipeline and bring new treatments to patients more quickly.